In keeping with the anti-tumoral activity of the non-canonical NF-κB pathway, Xiu and collaborators demonstrated that NIK stabilization suppressed (mixed lineage leukemia) MLL-AF9-induced AML in vivo via activation and inhibition of alterative and canonical NF-κB pathways, respectively. The gene discussed is KMT2A; the disease is acute myeloid leukemia.